Últimas noticias sobre HOOKIPA Pharma (NASDAQ:HOOK) Bolsa

HOOKIPA PHARMA INC

HOOKIPA Pharma

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.

HOOKIPA Pharma Inc

Hooker Furnishings Corporation - Common Stock

Hooker Furnishings Corp

News

FBRT

Franklin BSP Realty Trust Raises $107M Via Senior Notes For General Corporate Use, Potential NewPoint Acquisition

KBR JV HomeSafe Removed From U.S. TRANSCOM Household Goods Contract; No Impact Expected On 2025 Adjusted EBITDA

Financial commentator Peter Schiff expressed his intent to launch a gold-backed stablecoin Thursday, questioning the value of those backed by the U.S. dollar.
What Happened:&nbsp;Schiff responded to a comment on X that he should launch a gold-backed stablecoin.
&#8220;They already exist. But I&nbsp;do intend to launch my&nbsp;own,&#8221; Schiff replied. Many users soon converged on this post, with some even suggesting names for the initiative, such as SchiffCoin, while others called it a genuinely &#8220;good idea.&#8221;
It wasn&#8217;t immediately clear whether Schiff was making a joke or genuinely interested in tying cryptocurrency to the asset he passionately supports. Benzinga reached out to entities connected to Schiff, such as SchiffGold, to gather additional information. The article will be updated when they respond.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">They already exist. But I do intent to launch my own.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1935817013584109971?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The conversation started on his original post, where he called the dollar a &#8220;flawed&#8221; fiat currency and instead supported having a token purely backed by gold.
&#8220;I get Bitcoin, but not U.S. dollar stablecoins. If you&#8217;re going to introduce a third party custodian, why settle for a token backed by a flawed fiat currency like the dollar, when you can own one backed by gold?,&#8221; he stated.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I get Bitcoin, but not U.S. dollar stablecoins. If you&#39;re going to introduce a third party custodian, why settle for a token backed by a flawed fiat currency like the dollar, when you can own one backed by gold? You get the same liquidity, but you also get a real store of value.
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1935805977577619531?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Gold-backed stablecoins do exist, with Tether Gold (CRYPTO: XAUT) and PAX Gold (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/paxg/usd">PAXG</a>) among the most well-known. Year-to-date, the two coins have gained over 28%, matching the gains in the yellow metal.
See Also:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/06/45989307/senate-passes-genius-act-coinbases-brian-armstrong-calls-it-big-milestone-scott-bessent-says-passage-could-drive-stablecoins-into-a-3-7-trillion-market" target="_blank" rel="noreferrer noopener">Senate Passes GENIUS Act—Coinbase&#8217;s Brian Armstrong Calls It &#8216;Big Milestone,&#8217; Scott Bessent Says Passage Could Drive Stablecoins Into A $3.7 Trillion Market</a>
Why It Matters:&nbsp;Schiff&#8217;s views on stablecoins have been clear for some time. He has&nbsp;<a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46010451/peter-schiff-doesnt-think-stablecoins-will-help-preserve-dollar-dominance-heres-what-the-economist-says-theyll-do-instead">expressed doubts</a>&nbsp;about the potential of stablecoins to maintain the U.S. dollar's dominance, suggesting their primary use would be in cryptocurrency trading. 
The discussion around stablecoins has picked up momentum, especially after the passage of the stablecoin bill by the Senate. President&nbsp;Donald Trump&nbsp;<a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46009971/trump-cheers-incredible-stablecoin-bill-passed-by-senate-get-it-to-my-desk-asap-no-delays" target="_blank" rel="noreferrer noopener">praised the move</a>&nbsp;and urged Congress to get it on his desk without delay.
Interestingly, Schiff&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44212604/peter-schiff-establishes-personal-strategic-bitcoin-reserve-vows-not-to-sell-going-down-with-the-ship-so-others-never-get-on-board">established</a>&nbsp;a personal &#8216;Strategic Bitcoin Reserve,&#8217; promising not to sell any of it, in a move seen as a mockery of a similar declaration by President Donald Trump.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://benzinga.com/crypto/cryptocurrency/25/06/45939432/bitcoins-current-cycle-sees-a-656-surge-matching-market-maturation-pace" target="_blank" rel="noreferrer noopener">Bitcoin&#8217;s Current Cycle Sees A 656% Surge, Matching Market Maturation Pace</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$PAXG

Peter Schiff Says He Intends To Launch Gold-Backed Stablecoins, Deems Dollar As A 'Flawed' Fiat Currency

Shares of Cheetah Mobile Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) rose sharply in pre-market trading following <a href="https://www.benzinga.com/quote/cmcm/earnings">first-quarter results</a>.
Cheetah Mobile posted a quarterly loss of 11 cents per share, versus a year-ago loss of 32 cents per share. The company's quarterly sales rose to $35.69 million from $26.35 million in the year-ago period.
Cheetah Mobile shares surged 11.2% to $4.57 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Wheeler Real Estate Investment Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>) surged 129.6% to $7.85 in pre-market trading. On May 21, Wheeler Real Estate Investment Trust announced it will implement a 1-for-7 reverse stock split.</li>
<li>Dragonfly Energy Holdings Corp.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares jumped 108% to $0.4534 in pre-market trading after gaining 6% on Wednesday.</li>
<li>Baiya International Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) gained 36.2% to $1.13 in pre-market trading.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) jumped 32.2% to $0.32 in pre-market trading. On Tuesday, Processa Pharmaceuticals announced the pricing of $7 million public offering.</li>
<li>GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) rose 21.2% to $98.22 in pre-market trading. GMS confirmed the receipt of $95.20 per share unsolicited buyout proposal from QXO.</li>
<li>Beasley Broadcast Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) rose 19.5% to $5.57 in pre-market trading after gaining 5% on Wednesday.</li>
<li>Arqit Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQQ#NASDAQ">ARQQ</a>) gained 15.2% to $43.74 in pre-market trading after surging over 22% on Wednesday.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) fell 13.3% to $21.31 in pre-market trading after gaining more than 16% on Wednesday.</li>
<li>GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) climbed 10.4% to $1.02 in pre-market trading. GeoVax Labs recently in a filing disclosed it will sell 6.15 million common units.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) shares tumbled 52.8% to $2.66 in pre-market trading after surging over 142% on Wednesday.</li>
<li>Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares fell 16.2% to $52.96 in pre-market trading after dipping over 18% on Wednesday.</li>
<li>PTL Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLE#NASDAQ">PTLE</a>) dipped 16.2% to $0.30 in pre-market trading after surging 84% on Wednesday.</li>
<li>Cambium Networks Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) declined 12.9% to $0.36 in pre-market trading after gaining over 16% on Wednesday. Cambium Networks, last month, announced it received a Nasdaq noncompliance notice.</li>
<li>Smith &amp; Wesson Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) declined 12.6% to $9.51 in pre-market trading after the company reported worse-than-expected fourth-quarter EPS and sales.</li>
<li>Cellectar Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) dipped 12.4% to $0.32 in pre-market trading. Cellectar Biosciences announced a 1-for-30 reverse stock split, effective June 24.</li>
<li>QuantaSing Group Ltd- ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) fell 12.1% to $11.86 in pre-market trading.</li>
<li>Aptevo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) fell 11.9% to $4.52 in pre-market trading. Aptevo Therapeutics shares jumped 82% on Wednesday after the company announced clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig.</li>
<li>Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 7.4% to $11.04 in pre-market trading. Capricor Therapeutics recently announced Orphan Drug designation for Becker Muscular Dystrophy.</li>
<li>Mesoblast Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 6.5% to $10.94 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45993572/top-2-industrials-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Industrials Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

APVO

ARQQ

BBGI

BIYA

CAPR

CLRB

CMBM

CMCM

DFLI

GOVX

MESO

NWGL

OSCR

PCSA

PTLE

SWBI

WHLR

Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices.
What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (PBMs) and Big Pharma's tax practices, with the Senate poised to address reform amid rising public scrutiny.
Enter Cuban, the Dallas Mavericks owner and founder of Cost Plus Drugs, who fired back with a pointed correction.
In a post quoting Warren, Cuban argued that PBMs—not Big Pharma—are the true culprits behind inflated drug prices.
&#8220;PBMs corrupt healthcare,&#8221; he wrote, explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distortion">three major PBMs</a> negotiating over 90% of rebates for commercial insurance plans. 
Warren, in her post, had blamed pharmaceutical giants like Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) for charging Americans the &#8220;highest drug prices in the world&#8221; while paying &#8220;zero dollars in federal taxes.&#8221;
Citing data from her Senate Finance Committee role, Warren highlighted how these companies, alongside AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), have exploited tax loopholes from the 2017 Tax Cuts and Jobs Act to shield billions in profits.
&#8220;Republicans want to make it worse. I&#8217;m fighting back,&#8221; she declared, sharing <a href="https://www.cnbc.com/2025/06/17/pfizer-merck-jj-others-face-scrutiny-over-tax-loophole-extension.html">a</a> CNBC headline and urging action against what she calls a &#8220;rigged tax system.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No. It&#39;s because PBMs corrupt healthcare. Big Pharma wishes they could set their own pricing. They don&#39;t. PBMs control formularies and manipulate prices, in exchange for providing pharma access to patients. It&#39;s how they maximize rebate revenue. In fact, 3 PBMs NEGOTIATE… <a href="https://t.co/GpN4mnzvOM">https://t.co/GpN4mnzvOM</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1935705831930298562?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is ‘Massively Underestimating' This AI Play, Urges Investors To Look Beyond Mag 7</a>
Why It Matters: Cuban has been a c<a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">ritic of the healthcare system</a>, saying that it should be simple. According to him, it&#8217;s become overly complicated by big insurance companies and PBMs.
These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.
He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and &#8220;Sh–ing on&#8221; on independent pharmacies.
Some significant firms engaged in the PBM business listed in the U.S. include;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>51.15%</td>
<td>9.57%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>14.54%</td>
<td>-6.95%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-39.11%</td>
<td>-36.60%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, here is how some pharmaceutical sector ETFs have performed;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>1.69%</td>
<td>-4.48%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-0.49%</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.23%</td>
<td>-1.64%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.06%</td>
<td>2.61%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>20.55%</td>
<td>22.94%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-5.44%</td>
<td>-6.27%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.49%</td>
<td>-14.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Friday. The SPY was down 0.30% at $595.67, while the QQQ was 0.015% higher at $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46016347/this-stock-just-popped-30-in-5-days-now-expert-says-it-looks-potentially-explosive">This Stock Just Popped 30% In 5 Days — Now Expert Says It ‘Looks Potentially Explosive'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

Insurance

ABBV

AMGN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

Needham analyst Kyle Peterson reiterates Alight (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALIT#NYSE">ALIT</a>) with a Buy and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

ALIT

Needham Reiterates Buy on Alight, Maintains $8 Price Target

MNSO

MINISO Chairman Guofu Ye Unwinds Collar Transaction, Recovers 14M Shares Previously Transferred As Credit Support Under Prepaid Forward Contract

RYDE

Tencent Cloud Partners With Ryde Group To Boost In-App Ride-Hailing Communication In Southeast Asia Using TRTC And WeChat Mini Program

YUMC

Yum China Unveils Q-Smart, AI Assistant For Store Managers To Streamline Operations With Hands-Free Wearables And Voice-Controlled Insights

So-Young Amends Effective Date Of ADS Ratio Change To 1:15, Plans Reverse ADS Split With No Impact On Class A Shares Or Nasdaq Listing

<a href="https://www.wsj.com/business/deals/home-depot-bid-kicks-off-a-battle-for-5-billion-building-products-company-05cf2060?mod=Searchresults_pos2&amp;page=1" title="https://www.wsj.com/business/deals/home-depot-bid-kicks-off-a-battle-for-5-billion-building-products-company-05cf2060?mod=Searchresults_pos2&amp;page=1">https://www.wsj.com/business/deals/home-depot-bid-kicks-off-a-battle-for-5-billion-building-products-company-05cf2060?mod=Searchresults_pos2&amp;page=1</a>

The Wall Street Journal Reported Thursday, Home Depot Has Made An Offer To Acquire GMS

If you're thinking about investing in real estate right now—especially through a platform like Arrived Homes—it helps to look beyond the marketing headlines and get into the actual numbers. Two cities that keep popping up for investors are Memphis, Tennessee and Phoenix, Arizona. Both are active Arrived markets. But while they're both on the radar, they're moving in completely different directions in 2025.
Phoenix is growing fast, with new construction still ramping up and vacancy rates rising. Memphis, on the other hand, is tightening—fast. Supply is shrinking, rents are rising, and occupancy is pushing past 94% in the city's strongest submarkets. Whether you're looking for short-term cash flow, long-term appreciation, or just trying to make a smart entry into real estate, knowing how these two markets stack up is the key to deciding where your next dollar should go.
Related:
<ul class="wp-block-list">
<li>This Jeff Bezos-backed startup will allow you to <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=byerscta100">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.</li>
<li>Tired of waiting on the sidelines? <a href="http://groundfloor-finance.sjv.io/dOVZg7">With Groundfloor, you can invest in real estate projects with as little as $10 — no accredited investor status required</a>.</li>
</ul>
<h2 class="wp-block-heading">Tight Supply, Rising Rents, and Strong Cash Flow Potential</h2>
Memphis isn't flashy—but for real estate investors, that's kind of the point. What you get here is a stable, landlord-friendly market with rents that are rising, occupancy rates that are climbing, and home prices that are still within reach. Multifamily construction in Memphis has slowed to a crawl. New starts dropped 60% in 2024, and completions are down another 36% in 2025. That kind of supply squeeze is exactly what drives investor returns.
Occupancy is already strong—sitting at over 94% in East Memphis, Midtown, and Collierville—and net absorption is projected to outpace new deliveries by more than 50% this year. That means fewer units are coming online and the ones that do exist are filling fast. As a result, rents are beginning to climb again—between 2.4% and 4% depending on the neighborhood. That's especially encouraging after a relatively flat 2024.
Affordability is another key reason Memphis stands out. Median rents for all units range from $1,300 to $1,342, with one-bedroom apartments averaging around $1,100. Investors aren't paying a premium to enter this market either—median home prices are still hovering around $190,000. That makes Memphis one of the best cities in the U.S. for cash-flow-focused investing, especially if you're building a diversified portfolio through fractional ownership.
And unlike what we're seeing in oversupplied metros, concessions in Memphis are rare. Landlords don't need to offer free rent or move-in bonuses to fill their units. Demand is strong enough to stand on its own, and that puts investors in a great position to earn consistent, stable returns from day one.
<h2 class="wp-block-heading">High Vacancy, Heavy Concessions—but Long-Term Promise</h2>
Phoenix is almost the opposite story. It's still one of the fastest-growing cities in the country, with a steady stream of new residents relocating from California, the Midwest, and beyond. But in 2025, that population growth hasn't kept pace with the surge in new rental inventory. Active listings are up 20.5% year-over-year, vacancy is sitting at 7.5%—well above the national average—and over half of all listings (56%) are now offering concessions just to attract tenants.
For renters, that's great news. There's more selection, more negotiating power, and lots of opportunities to score deals. But for landlords and investors, the math is trickier. Rent growth has essentially stalled, up just 1.2% over the past year. Most property managers are projecting flat rent performance until 2026, when the excess supply is expected to get absorbed and growth potentially picks back up to 4–6%.
Phoenix is also more expensive on nearly every front. The average rent is $1,646—over $300 higher than Memphis—and larger units easily push past $2,100 per month. While that can translate to higher gross rents, it also means higher acquisition costs, greater tenant turnover risk, and a more competitive landscape for landlords trying to fill vacancies.
Still, Phoenix has something Memphis doesn't: scale and long-term upside. The city's economy continues to expand. Infrastructure is improving. And the west side, where much of the new supply is concentrated, is expected to stabilize over the next 12–18 months. For long-term investors who can handle softer returns in the short run, Phoenix could still deliver strong appreciation over time.
<h2 class="wp-block-heading">Which City Wins in 2025?</h2>
If you're asking which city gives you the better investment opportunity right now, the answer is simple: Memphis. It has rising rents, tightening supply, high occupancy, and investor-friendly prices. You don't need to offer tenant incentives. You don't need to worry about competing with hundreds of other landlords. And you can still buy into this market at a price point that leaves plenty of room for cash flow.
Phoenix, meanwhile, is better for renters in 2025. They're enjoying a rare moment of leverage—more supply, lower rent growth, and generous concessions. For investors, the current picture is more complicated. Yes, Phoenix still has long-term potential. But it's a tougher market right now. If you're investing in Phoenix, you're betting on the rebound—waiting for the oversupply to shake out and rent growth to resume.
But if you want to start earning reliable rental income now—not in 2026 or beyond—Memphis is where you want to be putting your capital today.
Take Action:
<ul class="wp-block-list">
<li>Put your money to work for you: In terms of getting money back, <a href="https://www.gobankingrates.com/best-banks-c/">these bank accounts put traditional checking and savings accounts to shame</a>.</li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=jeffbezos100"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>
<h3 class="wp-block-heading">Arrived Achieved A Total Return of 34.7% On Their Biggest Sale Yet — Diversify Your Monthly Income Stream With Fractional Real Estate</h3>
<a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=centennial">Arrived allows individuals to invest in shares of rental properties for as little as $100, providing the potential for monthly rental income and long-term appreciation without the hassles of being a landlord</a>. With over $1 million in dividends paid out last quarter and a growing selection of properties across various markets, Arrived offers an attractive alternative for investors seeking to build a diversified real estate portfolio. 
In October 2024, Arrived sold The Centennial, achieving a total return of 34.7% (11.2% average annual returns) for investors. <a href="https://arrivedhomes.go2cloud.org/aff_c?offer_id=15&amp;aff_id=1006&amp;aff_sub=yahoo&amp;aff_sub2=centennial">Arrived aims to continue delivering similar value across our portfolio through careful market selection, attentive property management, and thoughtful timing in sales.</a> Looking for fractional real estate investment opportunities? The <a href="https://www.benzinga.com/alternative-investments/real-estate">Benzinga Real Estate Screener</a> features the latest offerings.

Real Estate

Memphis vs. Phoenix: Which Rental Market Wins in 2025?

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is reportedly working on a 6-seater variant of the Model Y crossover SUV.
What Happened: "The much rumored about 6-seater Model Y made an appearance in the firmware," Electrek reported <a href="https://electrek.co/2025/06/19/tesla-hacker-reveals-new-model-y-with-6-seats/">on</a> Thursday, citing a post on X by Tesla leaker Green.
The report also said that the model does not appear to be "China-only as some of the speculations said."
Tesla currently offers a 6-seater variant in the Model X, while also offering 5- and 7-seater versions of the car.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The much rumored about 6-seater Model Y made an appearance in the firmware. Unlikely to be China-only as some of the speculations said. Some weird &quot;slow down to save energy, people typically drive this much slower here to save %%&quot; nav suggestions.
&mdash; green (@greentheonly) <a href="https://twitter.com/greentheonly/status/1934410913240481998?ref_src=twsrc%5Etfw">June 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The news comes in as Tesla is focused on the company's highly anticipated <a href="https://www.benzinga.com/markets/tech/25/06/45854273/elon-musks-tesla-officially-named-av-operator-in-austin-ahead-of-robotaxi-launch">Robotaxi launch</a> in Austin, Texas. CEO Elon Musk has said that the Robotaxi operation will initially include over 10 Model Y Robotaxis.
Tesla is also planning <a href="https://www.benzinga.com/news/25/06/46018296/tesla-will-shut-down-production-at-the-texas-gigafactory-over-the-4th-of-july-weekend">to shut down</a> its Texas Gigafactory over the Fourth of July Weekend to carry out some maintenance and repair work in the facility's production line.
What could also prove to be a major boost for the company is the NHTSA announcing an update to regulations, which aims to provide exemptions to Autonomous Vehicles in the U.S. <a href="https://www.benzinga.com/markets/tech/25/06/45942936/elon-musks-cybercab-ambitions-just-got-a-boost-as-nhtsa-eases-regulations-for-autonomous-vehicles">from the safety standards</a>.
Elsewhere, Musk also shared that the company <a href="https://www.benzinga.com/markets/tech/25/06/46019450/elon-musk-says-tesla-works-closely-with-xai-you-can-either-be-a-spectator">is working closely</a> with the billionaire's AI venture, xAI, to develop autonomous driving tech as well as humanoid robots.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="202" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20034941/tsla-jun-20-2025-1-1024x202.jpg" alt="" class="wp-image-955621" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20034941/tsla-jun-20-2025-1-1024x202.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20034941/tsla-jun-20-2025-1-300x59.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20034941/tsla-jun-20-2025-1-768x152.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20034941/tsla-jun-20-2025-1-1536x303.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20034941/tsla-jun-20-2025-1.jpg 1566w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Tesla scores well on Momentum, Quality and Growth metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45966726/tesla-vehicle-production-cost-1-7-that-of-waymo-elon-musks-ev-giant-closer-to-full-autonomy-than-competition-report">Tesla Vehicle Production Cost &#8216;1/7&#8217; That Of Waymo, Elon Musk&#8217;s EV Giant Closer To Full Autonomy Than Competition: Report</a></li>
</ul>
Photo courtesy: Ken Wolter / Shutterstock.com

Tech

TSLA

Elon Musk's Tesla To Expand Model Y Lineup With New 6-Seater Version: Report

<h3>Companies Reporting Before The Bell</h3>
• Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) is expected to report quarterly earnings at $2.97 per share on revenue of $3.26 billion. 
• CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) is estimated to report quarterly earnings at $1.17 per share on revenue of $7.53 billion. 
• Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) is estimated to report quarterly earnings at $3.32 per share on revenue of $17.32 billion. 
• Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) is projected to report quarterly earnings at $1.46 per share on revenue of $45.31 billion. 
<h3>Companies Reporting After The Bell</h3>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Scheduled For June 20, 2025

Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) says that its new affordable EV platform will match up to its Chinese counterparts on cost.
What Happened: Lisa Drake, Ford's Vice President for EVs Systems and Platform Programs, shared some insight into the Detroit-based automaker's EV plans with Bernstein analyst Daniel Roeska, Axiom reported <a href="https://www.axios.com/2025/06/18/ford-china-ev">on</a> Wednesday.
"Ford intends to match the cost structure of leading Chinese players. That means not just battery pricing, but full system cost from chassis and thermal systems to inverters and electronics," Roeska wrote. The report also gives a 2027 due date for the EV.
The analyst also said that the new platform will support over 8 body styles, including pickups, sedans and crossovers. "With eight body styles and potential global applicability, it&#8217;s intended to underpin Ford&#8217;s EV strategy for much of the next decade," Roeska said.
The company plans on using Prismatic LFP batteries, built in collaboration with Chinese battery giant CATL or Contemporary Amperex Technology Ltd. However, the batteries will be produced in the U.S., the report suggests.
Why It Matters: The news comes in as Ford reportedly opened its <a href="https://www.benzinga.com/25/05/45562915/ford-will-let-nissan-use-part-of-kentucky-battery-factory-could-this-be-a-scaling-back-on-ev-ambitions">doors for Nissan </a>to use the company's flagship EV battery production plant in Kentucky, amid a projected $5.5 billion loss on EVs in 2025.
The company has said that U.S. President Donald Trump's tariffs would cost them over $1.5 billion, with company executive chair Bill Ford also expressing concern about the GOP's proposal to axe the<a href="https://www.benzinga.com/trading-ideas/movers/25/06/45732185/whats-going-on-with-ford-stock-monday-2"> $7500 EV credit</a>.&nbsp;
The company also hiked prices of some of its<a href="https://www.benzinga.com/markets/25/05/45277938/ford-hikes-prices-of-select-mexico-produced-vehicles-amid-auto-tariff-uncertainty-report"> Mexico-produced EVs</a>, including the Mustang Mach-E, Bronco Sport and Maverick Pickup truck. It's worth noting that Ford produces over 80% of its vehicles domestically.
Elsewhere, the company had recently issued a recall for the <a href="https://www.benzinga.com/markets/tech/25/06/46012477/ford-recalls-over-197000-vehicles-for-backseat-issue-that-could-trap-occupants-in-emergency-situations">Mustang Mach-E</a> as well as the <a href="https://www.benzinga.com/markets/tech/25/06/45739688/ford-recalls-over-29500-f-150-lightning-pickup-trucks-over-suspension-defect">F150 Lightning EV</a> pickup truck over a rear seat occupant and suspension issue, respectively.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="207" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20031446/F-JUN-20-2025-1024x207.jpg" alt="" class="wp-image-955574" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20031446/F-JUN-20-2025-1024x207.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20031446/F-JUN-20-2025-300x61.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20031446/F-JUN-20-2025-768x155.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20031446/F-JUN-20-2025-1536x311.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/20031446/F-JUN-20-2025.jpg 1576w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Ford scores well on Value, Quality and Growth metrics, while offering satisfactory Momentum. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45208083/ford-stock-hits-the-brakes-after-q1-earnings-suspends-guidance-due-to-tariff-related-uncertainty">Ford Stock Hits The Brakes After Q1 Earnings, Suspends Guidance Due To &#8216;Tariff-Related Uncertainty&#8217;</a></li>
</ul>
Photo courtesy: Tada Images / Shutterstock.com

Ford Says Upcoming Budget EV Platform Will Rival Chinese EV Prices: Report

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>, "Telix", "the Company") today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24.
Presentation highlights include the ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer, preclinical data on Telix's TLX252 alpha therapy candidate in CAIX1 -expressing tumors in combination with DDRIs2, and clinical study data on Illuccix&#xAE; impact on decision-making.
Two sponsored symposia will highlight innovation in precision diagnostics, the first on CAIX-PET3 imaging in renal cancer, and the second on Illuccix PSMA-PET4 imaging in prostate cancer, including Telix's new PSMA biopsy trial.
Dr. David N. Cade, Group Chief Medical Officer, Telix, said, "Telix's broad representation at this year's SNMMI Annual Meeting highlights the strength of our innovative pipeline and commercial programs. Our sponsored symposia, featuring leading key opinion leaders, further reflect our commitment to expanding clinical utility and advancing cancer care so that more patients may benefit from precision theranostics."
Visit booth #408 to discuss Telix's extensive theranostic portfolio in urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), hematologic oncology, its investigational pan-cancer programs, medical technologies, and opportunities for collaboration.

Telix Showcases Prostate and Kidney Cancer Breakthroughs at US Medical Imaging Conference

FinVolution Group ("FinVolution" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>), a leading fintech platform in China, Indonesia and the Philippines, today announced a proposed offering (the "Notes Offering") of convertible senior notes in an aggregate principal amount of US$130 million due 2030 (the "Notes"), subject to market conditions and other factors, only to persons reasonably believed to be qualified institutional buyers pursuant to Rule&nbsp;144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company intends to grant the initial purchasers in the Notes Offering an option to purchase up to an additional US$20 million in aggregate principal amount of the Notes, exercisable for settlement within a 13-day period beginning on, and including, the date on which the Notes are first issued.
The Company plans to use the net proceeds from the Notes Offering for (i) international business expansions, (ii) replenishment of working capital, and (iii) funding the Concurrent Repurchase (as described below).
Proposed Terms of the Notes
When issued, the Notes will be senior, unsecured obligations of the Company. The Notes will mature on July 1, 2030 unless repurchased, redeemed, or converted in accordance with their terms prior to such date.
Holders may convert their Notes at their option at any time prior to the close of business on the third scheduled trading day immediately preceding the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, ADSs, each representing five Class A ordinary shares of the Company, or a combination of cash and ADSs, at the Company's election. The interest rate, initial conversion rate and other terms of the Notes will be determined at the time of pricing of the Notes Offering.
Holders of the Notes may require the Company to repurchase all or part of their Notes for cash on July 3, 2028 or in the event of certain fundamental changes, in each case, at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased,&nbsp;plus&nbsp;accrued and unpaid interest, if any, to, but excluding, the relevant repurchase date. Furthermore, the Company may redeem all but not part of the Notes in the event of certain changes in the tax laws or if less than 10% of the aggregate principal amount of the Notes originally issued remains outstanding at such time, in each case, at a redemption price equal to 100% of the principal amount of the Notes to be redeemed,&nbsp;plus&nbsp;accrued and unpaid interest, if any, to, but excluding, the related redemption date. Any redemption may occur only prior to the 92nd scheduled trading day immediately preceding the maturity date.
Concurrent Repurchase
Concurrently with the pricing of the Notes Offering, the Company plans to repurchase a number of ADSs to be determined at the time of pricing of the Notes Offering from certain purchasers of the Notes in off-market privately negotiated transactions effected through one of the initial purchasers or its affiliates, as the Company's agent (such transactions, the "Concurrent Repurchase"). The Concurrent Repurchase is expected to facilitate the initial hedging by purchasers of the Notes who desire to hedge their investments in the Notes, as the Company intends to repurchase the entire initial delta of the transaction. This will allow such purchasers of the Notes to establish short positions that generally correspond to commercially reasonable initial hedges of their investments in the Notes. The Concurrent Repurchase will be made pursuant to the Company's existing share repurchase programs announced in August 2023 and March 2025. The Company expects the purchase price in the Concurrent Repurchase to be the last reported sale price per ADS on the New York Stock Exchange on June 18, 2025.

Offerings

Buybacks

FINV

FinVolution Plans $130M Convertible Note Offering to Fuel Global Expansion and Share Buybacks

Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Joe Burnett as director of Bitcoin strategy. Semler Scientific also announced that it plans to hold 10,000 Bitcoins by year-end 2025, 42,000 by year-end 2026 and 105,000 by year-end 2027, using proceeds from equity and debt financings and cash flows from operations.&nbsp;

SMLR

Semler Scientific Names Bitcoin Strategy Chief, Plans to Hold 105,000 BTC by 2027

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgenasys.com%2F&amp;esheet=54279715&amp;newsitemid=20250619449768&amp;lan=en-US&amp;anchor=Genasys+Inc.&amp;index=1&amp;md5=562a7f6bc4149d4b2e7fd8c3e978f841">Genasys Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>), the global leader In <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgenasys.com%2Fgenasys-protect-platform%2F&amp;esheet=54279715&amp;newsitemid=20250619449768&amp;lan=en-US&amp;anchor=Protective+Communications&amp;index=2&amp;md5=13e39f97743529d5a06ec19860291593">Protective Communications</a>, today announced increasing interest and orders for <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgenasys.com%2Fgenasys-connect%2F&amp;esheet=54279715&amp;newsitemid=20250619449768&amp;lan=en-US&amp;anchor=CONNECT&amp;index=3&amp;md5=18ecf206cb7299427a22bee84dc81e6c">CONNECT</a>, the company's fully compliant, mission-critical communications platform for government and law enforcement.
"Greater demand for CONNECT has been spurred by the ‘Signalgate' controversy, where several members of the federal government used the Signal messaging app for sensitive information sharing," said Chief Jeff Halstead (Ret.), Genasys Senior Director of Strategic Accounts. "Since the controversy, we are experiencing increasing demand for CONNECT information, demonstrations and orders from public safety leaders in small towns and large metro areas across the United States."
To date, strong order demand and contract renewals have grown CONNECT coverage in 41 states and more than 500 agencies, with other states and multiple agencies in deployment trials.

GNSS

Genasys CONNECT Expands to 500+ Agencies Amid Rising Demand for Secure Public Safety Communication

Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), a global leader in photonics, today announces major enhancements to its FACTOR series of fiber-coupled diode pumps. The upgraded portfolio now offers increased output power, improved efficiency, and a wider locking range for pump modules at 976 nm. In addition, a new high-power pump module at 793 nm has been introduced to support growing demand in medical and industrial laser applications.
OEM laser manufacturers can benefit significantly from the FACTOR series, which offers reliable performance through automated, in-house micro-optics assembly that ensures high consistency and reliability. Designed for effortless integration, the system simplifies handling and installation, making it easy to incorporate into existing OEM laser systems. Additionally, the FACTOR series is volume-ready, supporting scalable manufacturing to meet high-volume demands and align with planned production cycles.

COHR

Coherent Upgrades FACTOR Laser Pumps With More Power and Efficiency for Medical and Industrial Use

Press Releases

Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm

General

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Health Care

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

Comments

HOOKIPA Pharma

Noticias

Últimas noticias sobre HOOKIPA Pharma (NASDAQ:HOOK) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL